Hua-Li Pharmaceuticals Obtains Dozagliatin's License for Drug Production

yesterday, Huali Pharmaceuticals announced that it had obtained a "Drug Production License" issued by the Shanghai Municipal Drug Administration to study the world's first innovative drug, dorzagliatin, after a system of approval and on-site verification by the Drug Market Licensing Holders (MAH).Since this year, Hua-Yuan Pharmaceuticals has successfully completed two key milestones in the registration of clinical trials for the listing of two new phase III drugs, including the Phase III clinical trial SEED (HMM0301) for the single-drug treatment of Dozagliatin in patients with undigested type 2 diabetes, and the clinical trial OFN (HMM0302) for a combined drug trial of metformin in patients with type 2 diabetes who failed to complete the treatment of metformin. Clinical studies show that during the corresponding treatment cycle, Dozagliatin has shown remarkable stability and safety, and has the effect of improving islet β cellular function, promoting early insulin secretion and reducing insulin resistance, which is expected to fundamentally treat diabetes. On August 17th, Huali Pharmaceuticals and Bayer announced the establishment of a strategic cooperation agreement on Dozagliatin in China. General Hua is responsible for the clinical development of products, production and supply, distribution of primary dealers, registration and drug alert, bayer as the exclusive promoter of Dozagliatin China, responsible for its marketing, promotion and medical education activities in China, China Collar Pharmaceuticals received a down payment of 300 million yuan, will also receive a milestone payment of up to 4.18 billion yuan. (U.S. News Agency)